Free Trial

YS Biopharma Q1 2024 Earnings Report

YS Biopharma EPS Results

Actual EPS
-$0.10
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

YS Biopharma Revenue Results

Actual Revenue
$24.40 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

YS Biopharma Announcement Details

Quarter
Q1 2024
Time
N/A

Conference Call Resources

Why Buffett, Griffin and 100 members of Congress are Piling into this One Investment (Ad)

This isn't just another investment. It might be the last retirement stock you'll ever need. But this window of opportunity is closing fast.

Click here for the ticker >>>

YS Biopharma Earnings Headlines

LakeShore Biopharma Co Ltd Ordinary Shares LSB
Why Buffett, Griffin and 100 members of Congress are Piling into this One Investment
This isn't just another investment. It might be the last retirement stock you'll ever need. But this window of opportunity is closing fast.
LSB LakeShore Biopharma Co., Ltd
See More YS Biopharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like YS Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on YS Biopharma and other key companies, straight to your email.

About YS Biopharma

YS Biopharma (NASDAQ:YSB) Co., Ltd., a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. The company develops a proprietary PIKA immunomodulating technology platform and a series of product targeting PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001. It operates in China, the United States, Singapore, the United Arab Emirates, and the Philippines. The company was founded in 2002 and is based in Beijing, China.

View YS Biopharma Profile

More Earnings Resources from MarketBeat

Upcoming Earnings